<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2023-6-136-142</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1514</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СОВЕТ ЭКСПЕРТОВ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERT ADVICE</subject></subj-group></article-categories><title-group><article-title>Резолюция Совета экспертов «Итоги многоцентрового рандомизированного двойного слепого плацебо-контролируемого исследования Артнео у пациентов с первичным остеоартритом коленного сустава II–III стадии</article-title><trans-title-group xml:lang="en"><trans-title>Resolution of the Council of Experts “Results of a multicenter, randomized, double-blind, placebo-controlled study of ARTNEO in patients with stage II–III primary knee osteoarthritis”</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6068-3080</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лила</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Lila</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А;</p><p>кафедра ревматологии, 125993, Москва, ул. Баррикадная, 2/1, стр.1</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522;</p><p>Department of Rheumatology, 2/1, Barrikadnaya Street, Build. 1, Moscow 125993</p></bio><email xlink:type="simple">amlila@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7017-0898</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алексеева</surname><given-names>Л. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Alekseeva</surname><given-names>L. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А;</p><p>кафедра ревматологии, 125993, Москва, ул. Баррикадная, 2/1, стр.1</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522;</p><p>Department of Rheumatology, 2/1, Barrikadnaya Street, Build. 1, Moscow 125993</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7981-6349</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Беляева</surname><given-names>И. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Belyaeva</surname><given-names>I. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>191015, Санкт-Петербург, Кирочная ул., 41</p></bio><bio xml:lang="en"><p>41, Kirochnaya Street, St. Petersburg 191015</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5052-912X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Виноградова</surname><given-names>И. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Vinogradova</surname><given-names>I. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>432063, Ульяновск, ул. 3-го Интернационала, 7</p></bio><bio xml:lang="en"><p>7, III Internatzional Street, Ulyanovsk 432063</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6890-8777</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Демидова</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Demidova</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>117997, Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>1, Ostrovitianov Street, Moscow 117997</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3628-2436</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Калюжин</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kalyuzhin</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119048, Москва, Трубецкая ул. 8, стр. 2</p></bio><bio xml:lang="en"><p>8, Trubetskaya Street, Build. 2, Moscow 119991</p></bio><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3199-9537</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нестерович</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Nesterovich</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197022, Санкт-Петербург, ул. Льва Толстого, 6–8</p></bio><bio xml:lang="en"><p>6–8, Lva Tolstogo Street, Saint-Petersburg 197022</p></bio><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3684-7310</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сороцкая</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Sorotskaya</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>300028, Тула, ул. Болдина, 128</p></bio><bio xml:lang="en"><p>128, Boldin Street, Tula 300028</p></bio><xref ref-type="aff" rid="aff-7"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7058-9410</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Широкова</surname><given-names>Л. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Shirokova</surname><given-names>L. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>150000, Ярославль, ул. Революционная, 5</p></bio><bio xml:lang="en"><p>5, Revolutzionnaya Street, Yaroslavl 150000</p></bio><xref ref-type="aff" rid="aff-8"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8590-4839</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Якупова</surname><given-names>С. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakupova</surname><given-names>S. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>420012, Казань, ул. Бутлерова, 49</p></bio><bio xml:lang="en"><p>49, Butlerov Street, Kazan 420012</p></bio><xref ref-type="aff" rid="aff-9"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»;&#13;
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального&#13;
образования» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology;&#13;
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>North-Western State Medical University named after I.I. Mechnikov, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГУЗ «Ульяновская областная клиническая больница»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ulyanovsk Regional Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет&#13;
им. И.П. Павлова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pavlov First Saint-Petersburg State Medical University (Pavlov University), Ministry&#13;
of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-7"><aff xml:lang="ru"><institution>ФГБОУ ВО «Тульский государственный университет», Медицинский институт</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tula State University, Medical Institute</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-8"><aff xml:lang="ru"><institution>ФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Yaroslavl State Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-9"><aff xml:lang="ru"><institution>ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan State Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>21</day><month>12</month><year>2023</year></pub-date><volume>17</volume><issue>6</issue><fpage>136</fpage><lpage>142</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лила А.М., Алексеева Л.И., Беляева И.Б., Виноградова И.Б., Демидова Н.А., Калюжин О.В., Нестерович И.И., Сороцкая В.Н., Широкова Л.Ю., Якупова С.П., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Лила А.М., Алексеева Л.И., Беляева И.Б., Виноградова И.Б., Демидова Н.А., Калюжин О.В., Нестерович И.И., Сороцкая В.Н., Широкова Л.Ю., Якупова С.П.</copyright-holder><copyright-holder xml:lang="en">Lila A.M., Alekseeva L.I., Belyaeva I.B., Vinogradova I.B., Demidova N.A., Kalyuzhin O.V., Nesterovich I.I., Sorotskaya V.N., Shirokova L.Y., Yakupova S.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1514">https://mrj.ima-press.net/mrj/article/view/1514</self-uri><abstract><p>31 августа 2023 г. в ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» состоялось заседание Совета экспертов с участием главных исследователей и соисследователей по протоколу Artneo-2021 «Многоцентровое рандомизированное двойное слепое плацебо-контролируемое исследование Артнео у пациентов с первичным остеоартритом коленного сустава II–III стадии». Разработана согласованная позиция в отношении возможности и целесообразности использования комбинации неденатурированного (нативного) коллагена II типа, метилсульфонилметана, босвеллиевых кислот, витаминов С и D (комплекс Артнео) в клинической практике. Основываясь на результатах исследования, в составе комплексной терапии пациентов с остеоартритом может быть рекомендовано применение комплекса Артнео общим курсом до 6 мес. Результаты исследования могут быть интерпретированы только по отношению к Артнео и не могут распространяться на композиции с иным составом.</p></abstract><trans-abstract xml:lang="en"><p>On August 31,2023 in V.A. Nasonova Research Institute of Rheumatology a meeting of the Expert Council was held at which the principal investigators and co-investigators of the ARTNEO-2021 protocol "Multicenter randomized double-blind, placebo-controlled study of ARTNEO in patients with stage II-III primary knee osteoarthritis" was held. A consensus position was developed on the possibility and feasibility of using a combination of undenatured (native) type II collagen, methylsulfonylmethane, boswellic acids, vitamins C and D (ARTNEO complex) in clinical practice. Based on the results of the study, the use of the ARTNEO complex can be recommended as part of a complex therapy for patients with osteoarthritis as a course treatment with total duration up to 6 months. The results of the study can only be interpreted in relation to ARTNEO and cannot be transferred to preparations with a different composition.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>остеоартрит</kwd><kwd>гонартроз</kwd><kwd>Артнео</kwd><kwd>неденатурированный (нативный) коллаген II типа</kwd><kwd>оральная иммунная толерантность</kwd><kwd>босвеллиевые кислоты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>osteoarthritis</kwd><kwd>gonarthrosis</kwd><kwd>ARTNEO</kwd><kwd>undenatured (native) type II collagen</kwd><kwd>oral immune tolerance</kwd><kwd>boswellic acids</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Статья спонсируется компанией ООО «НПО Петровакс Фарм».</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Yao Q, Wu X, Tao C, et al. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct Target Ther. 2023 Feb 3;8(1):56. doi: 10.1038/s41392-023-01330-w.</mixed-citation><mixed-citation xml:lang="en">Yao Q, Wu X, Tao C, et al. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct Target Ther. 2023 Feb 3;8(1):56. doi: 10.1038/s41392-023-01330-w.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Hawker GA, King LK. The Burden of Osteoarthritis in Older Adults. Clin Geriatr Med. 2022 May;38(2):181-192. doi: 10.1016/j.cger.2021.11.005.</mixed-citation><mixed-citation xml:lang="en">Hawker GA, King LK. The Burden of Osteoarthritis in Older Adults. Clin Geriatr Med. 2022 May;38(2):181-192. doi: 10.1016/j.cger.2021.11.005.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Favero M, Belluzzi E, Ortolan A, et al. Erosive hand osteoarthritis: latest findings and outlook. Nat Rev Rheumatol. 2022 Mar;18(3): 171-183. doi: 10.1038/s41584-021-00747-3. Epub 2022 Feb 1.</mixed-citation><mixed-citation xml:lang="en">Favero M, Belluzzi E, Ortolan A, et al. Erosive hand osteoarthritis: latest findings and outlook. Nat Rev Rheumatol. 2022 Mar;18(3): 171-183. doi: 10.1038/s41584-021-00747-3. Epub 2022 Feb 1.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Conaghan PG, Abraham L, Graham-Clarke P, et al. OP0190 Understanding current prescription drug treatment paradigms for patients with osteoarthritis in Europe. Ann Rheum Dis. 2020;79:118.</mixed-citation><mixed-citation xml:lang="en">Conaghan PG, Abraham L, Graham-Clarke P, et al. OP0190 Understanding current prescription drug treatment paradigms for patients with osteoarthritis in Europe. Ann Rheum Dis. 2020;79:118.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Namba RS, Inacio MC, Pratt NL, et al. Postoperative opioid use as an early indication of total hip arthroplasty failure. Acta Orthop. 2016 Jul;87 Suppl 1(Suppl 1):37-43. doi: 10.1080/17453674.2016.1181820. Epub 2016 May 11.</mixed-citation><mixed-citation xml:lang="en">Namba RS, Inacio MC, Pratt NL, et al. Postoperative opioid use as an early indication of total hip arthroplasty failure. Acta Orthop. 2016 Jul;87 Suppl 1(Suppl 1):37-43. doi: 10.1080/17453674.2016.1181820. Epub 2016 May 11.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Conley B, Bunzli S, Bullen J, et al. Core Recommendations for Osteoarthritis Care: A Systematic Review of Clinical Practice Guidelines. Arthritis Care Res (Hoboken). 2023 Sep;75(9):1897-1907. doi: 10.1002/acr.25101. Epub 2023 Mar 17.</mixed-citation><mixed-citation xml:lang="en">Conley B, Bunzli S, Bullen J, et al. Core Recommendations for Osteoarthritis Care: A Systematic Review of Clinical Practice Guidelines. Arthritis Care Res (Hoboken). 2023 Sep;75(9):1897-1907. doi: 10.1002/acr.25101. Epub 2023 Mar 17.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Резолюция консенсуса экспертов Российской Федерации по диагностике и лечению остеоартрита для врачей первичного звена. Терапия. 2022;8(5):119-128.</mixed-citation><mixed-citation xml:lang="en">Resolution of the consensus of experts of the Russian Federation on the diagnosis and treatment of osteoarthritis for primary care physicians. Terapiya. 2022;8(5):119-128. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Honvo G, Lengele L, Charles A, et al. Role of Collagen Derivatives in Osteoarthritis and Cartilage Repair: A Systematic Scoping Review With Evidence Mapping. Rheumatol Ther. 2020 Dec;7(4):703-740. doi: 10.1007/s40744-020-00240-5. Epub 2020 Oct 17.</mixed-citation><mixed-citation xml:lang="en">Honvo G, Lengele L, Charles A, et al. Role of Collagen Derivatives in Osteoarthritis and Cartilage Repair: A Systematic Scoping Review With Evidence Mapping. Rheumatol Ther. 2020 Dec;7(4):703-740. doi: 10.1007/s40744-020-00240-5. Epub 2020 Oct 17.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutr J. 2016 Jan 29;15:14. doi: 10.1186/s12937-016-0130-8.</mixed-citation><mixed-citation xml:lang="en">Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutr J. 2016 Jan 29;15:14. doi: 10.1186/s12937-016-0130-8.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Crowley DC, Lau FC, Sharma P, et al. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. Int J Med Sci. 2009 Oct 9;6(6):312-21. doi: 10.7150/ijms.6.312.</mixed-citation><mixed-citation xml:lang="en">Crowley DC, Lau FC, Sharma P, et al. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. Int J Med Sci. 2009 Oct 9;6(6):312-21. doi: 10.7150/ijms.6.312.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Liu X, Machado GC, Eyles JP, et al. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018 Feb;52(3):167-175. doi: 10.1136/bjsports-2016-097333. Epub 2017 Oct 10.</mixed-citation><mixed-citation xml:lang="en">Liu X, Machado GC, Eyles JP, et al. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018 Feb;52(3):167-175. doi: 10.1136/bjsports-2016-097333. Epub 2017 Oct 10.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Nagler-Anderson C, Bober LA, Robinson ME, et al. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7443-6. doi: 10.1073/pnas.83.19.7443.</mixed-citation><mixed-citation xml:lang="en">Nagler-Anderson C, Bober LA, Robinson ME, et al. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7443-6. doi: 10.1073/pnas.83.19.7443.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Milojevic D, Nguyen KD, Wara D, Mellins ED. Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development. Pediatr Rheumatol Online J. 2008 Dec 1:6:20. doi: 10.1186/1546-0096-6-20.</mixed-citation><mixed-citation xml:lang="en">Milojevic D, Nguyen KD, Wara D, Mellins ED. Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development. Pediatr Rheumatol Online J. 2008 Dec 1:6:20. doi: 10.1186/1546-0096-6-20.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Tordesillas L, Berin MC. Mechanisms of Oral Tolerance. Clin Rev Allergy Immunol. 2018 Oct;55(2):107-117. doi: 10.1007/s12016-018-8680-5.</mixed-citation><mixed-citation xml:lang="en">Tordesillas L, Berin MC. Mechanisms of Oral Tolerance. Clin Rev Allergy Immunol. 2018 Oct;55(2):107-117. doi: 10.1007/s12016-018-8680-5.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol. 2006 Jun-Dec; 13(2-4):143-57. doi: 10.1080/17402520600876804.</mixed-citation><mixed-citation xml:lang="en">Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol. 2006 Jun-Dec; 13(2-4):143-57. doi: 10.1080/17402520600876804.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bagchi D, Misner B, Bagchi M, et al. Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int J Clin Pharmacol Res. 2002;22(3-4):101-10.</mixed-citation><mixed-citation xml:lang="en">Bagchi D, Misner B, Bagchi M, et al. Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int J Clin Pharmacol Res. 2002;22(3-4):101-10.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Collagenase and rheumatoid arthritis. N Engl J Med. 1968 Oct 24;279(17):942-3. doi: 10.1056/NEJM196810242791710.</mixed-citation><mixed-citation xml:lang="en">Collagenase and rheumatoid arthritis. N Engl J Med. 1968 Oct 24;279(17):942-3. doi: 10.1056/NEJM196810242791710.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Mabbott NA, Donaldson DS, Ohno H, et al. Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium. Mucosal Immunol. 2013 Jul;6(4):666-77. doi: 10.1038/mi.2013.30. Epub 2013 May 22.</mixed-citation><mixed-citation xml:lang="en">Mabbott NA, Donaldson DS, Ohno H, et al. Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium. Mucosal Immunol. 2013 Jul;6(4):666-77. doi: 10.1038/mi.2013.30. Epub 2013 May 22.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Pabst O, Mowat AM. Oral tolerance to food protein. Mucosal Immunol. 2012 May; 5(3):232-9. doi: 10.1038/mi.2012.4. Epub 2012 Feb 8.</mixed-citation><mixed-citation xml:lang="en">Pabst O, Mowat AM. Oral tolerance to food protein. Mucosal Immunol. 2012 May; 5(3):232-9. doi: 10.1038/mi.2012.4. Epub 2012 Feb 8.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Wambre E, Jeong D. Oral Tolerance Development and Maintenance. Immunol Allergy Clin North Am. 2018 Feb;38(1):27-37. doi: 10.1016/j.iac.2017.09.003. Epub 2017 Oct 26.</mixed-citation><mixed-citation xml:lang="en">Wambre E, Jeong D. Oral Tolerance Development and Maintenance. Immunol Allergy Clin North Am. 2018 Feb;38(1):27-37. doi: 10.1016/j.iac.2017.09.003. Epub 2017 Oct 26.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Lv Z, Yang YX, Li J, et al. Molecular Classification of Knee Osteoarthritis. Front Cell Dev Biol. 2021 Aug 27;9:725568. doi: 10.3389/fcell.2021.725568.</mixed-citation><mixed-citation xml:lang="en">Lv Z, Yang YX, Li J, et al. Molecular Classification of Knee Osteoarthritis. Front Cell Dev Biol. 2021 Aug 27;9:725568. doi: 10.3389/fcell.2021.725568.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">National Academies of Sciences, Engineering, and Medicine. Developing Multimodal Therapies for Brain Disorders: Proceedings of a Workshop. Washington: The National Academies Press; 2017.</mixed-citation><mixed-citation xml:lang="en">National Academies of Sciences, Engineering, and Medicine. Developing Multimodal Therapies for Brain Disorders: Proceedings of a Workshop. Washington: The National Academies Press; 2017.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Mahajan R, Rathod NR, Narayanan V. (2019). Multimodal Anti-Inflammatory Approach to Osteoarthritis Management – Review of T Cell Immunomodulation with Undenatured (Native) Collagen Type II, and LOX Inhibition with Boswellia. Nov Tech Arthritis Bone Res. 2019;3(4):555618. doi: 10.19080/NTAB.2019.03.555618.</mixed-citation><mixed-citation xml:lang="en">Mahajan R, Rathod NR, Narayanan V. (2019). Multimodal Anti-Inflammatory Approach to Osteoarthritis Management – Review of T Cell Immunomodulation with Undenatured (Native) Collagen Type II, and LOX Inhibition with Boswellia. Nov Tech Arthritis Bone Res. 2019;3(4):555618. doi: 10.19080/NTAB.2019.03.555618.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Zapata A, Fernandez-Parra R. Management of Osteoarthritis and Joint Support Using Feed Supplements: A Scoping Review of Undenatured Type II Collagen and Boswellia serrata. Animals (Basel). 2023 Feb 27;13(5): 870. doi: 10.3390/ani13050870.</mixed-citation><mixed-citation xml:lang="en">Zapata A, Fernandez-Parra R. Management of Osteoarthritis and Joint Support Using Feed Supplements: A Scoping Review of Undenatured Type II Collagen and Boswellia serrata. Animals (Basel). 2023 Feb 27;13(5): 870. doi: 10.3390/ani13050870.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Jain AV, Jain KA, Vijayaraghavan N. AflaB2® and Osteoarthritis: A Multicentric, Observational, Post-Marketing Surveillance Study in Indian Patients Suffering from Knee Osteoarthritis. Int J Res Orthop. 2021 Jan;7(1): 110-115. doi: 10.18203/issn.2455-4510. IntJResOrthop20205570.</mixed-citation><mixed-citation xml:lang="en">Jain AV, Jain KA, Vijayaraghavan N. AflaB2® and Osteoarthritis: A Multicentric, Observational, Post-Marketing Surveillance Study in Indian Patients Suffering from Knee Osteoarthritis. Int J Res Orthop. 2021 Jan;7(1): 110-115. doi: 10.18203/issn.2455-4510. IntJResOrthop20205570.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Sadigursky D, Sanches M, Garcia N, et al. Effectiveness of the use of non-hydrolysed type II collagen in the treatment of osteoarthritis: a systematic review and meta-analysis. Brazilian Journal of Health Review. 2023; 6(1):1649-1660. doi:10.34119/bjhrv6n1-131.</mixed-citation><mixed-citation xml:lang="en">Sadigursky D, Sanches M, Garcia N, et al. Effectiveness of the use of non-hydrolysed type II collagen in the treatment of osteoarthritis: a systematic review and meta-analysis. Brazilian Journal of Health Review. 2023; 6(1):1649-1660. doi:10.34119/bjhrv6n1-131.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Yu G, Xiang W, Zhang T, et al. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complement Med Ther. 2020 Jul 17;20(1):225. doi: 10.1186/s12906-020-02985-6.</mixed-citation><mixed-citation xml:lang="en">Yu G, Xiang W, Zhang T, et al. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complement Med Ther. 2020 Jul 17;20(1):225. doi: 10.1186/s12906-020-02985-6.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. Cochrane Database Syst Rev. 2014 May 22;2014(5): CD002947. doi: 10.1002/14651858. CD002947.pub2.</mixed-citation><mixed-citation xml:lang="en">Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. Cochrane Database Syst Rev. 2014 May 22;2014(5): CD002947. doi: 10.1002/14651858. CD002947.pub2.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Gwinnutt JM, Wieczorek M, Rodriguez-Carrio J, et al. Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open. 2022 Jun; 8(2):e002167. doi: 10.1136/rmdopen-2021-002167.</mixed-citation><mixed-citation xml:lang="en">Gwinnutt JM, Wieczorek M, Rodriguez-Carrio J, et al. Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open. 2022 Jun; 8(2):e002167. doi: 10.1136/rmdopen-2021-002167.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Neogi T, Colloca L. Placebo effects in osteoarthritis: implications for treatment and drug development. Nat Rev Rheumatol. 2023 Oct;19(10):613-626. doi: 10.1038/s41584- 023-01021-4. Epub 2023 Sep 11.</mixed-citation><mixed-citation xml:lang="en">Neogi T, Colloca L. Placebo effects in osteoarthritis: implications for treatment and drug development. Nat Rev Rheumatol. 2023 Oct;19(10):613-626. doi: 10.1038/s41584- 023-01021-4. Epub 2023 Sep 11.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Wen X, Luo J, Mai Y, et al. Placebo Response to Oral Administration in Osteoarthritis Clinical Trials and Its Associated Factors: A Model-Based Meta-analysis. JAMA Netw Open. 2022 Oct 3;5(10):e2235060. doi: 10.1001/jamanetworkopen.2022.35060.</mixed-citation><mixed-citation xml:lang="en">Wen X, Luo J, Mai Y, et al. Placebo Response to Oral Administration in Osteoarthritis Clinical Trials and Its Associated Factors: A Model-Based Meta-analysis. JAMA Netw Open. 2022 Oct 3;5(10):e2235060. doi: 10.1001/jamanetworkopen.2022.35060.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Lane NE, Hochberg MC, Nevitt MC, et al. OARSI clinical trials recommendations: design and conduct of clinical trials for hip osteoarthritis. Osteoarthritis Cartilage. 2015 May;23(5):761-71. doi: 10.1016/j.joca.2015.03.006.</mixed-citation><mixed-citation xml:lang="en">Lane NE, Hochberg MC, Nevitt MC, et al. OARSI clinical trials recommendations: design and conduct of clinical trials for hip osteoarthritis. Osteoarthritis Cartilage. 2015 May;23(5):761-71. doi: 10.1016/j.joca.2015.03.006.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
